Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6255320A · kind A · utility
1Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2000 |
| Grant date | Jul 3, 2001 |
| Priority date | — |
| Expiry date | May 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A single crystalline polymorphic form (2S,3S)-N-(methoxy-5-t-butylphenylmethyl-2-diphenylmethyl-1-azobicyclo[2,2 ,2] octan-3-amine citrate(citrate monohydrate) and its pharmaceutical composition. The pharmaceutical composition of the polymorphic form if the citrate monohydrate has advantageous stability for formulation to treat emesis. The administration of this pharmaceutical composition is immediate release, oral dosage form preferably by tablet or capsule or intravenous.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.